Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eli Zuckerman

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|April 11, 2026
EXPRESS: Adherence and Sustained Virologic Response in HCV Treatment: A Real-World Comparison of Major Pangenotypic Direct-Acting AntiviralsFadi Abu Baker, Rawi Hazzan, Tarek Saadi, et al.
Harefuah|January 22, 2013
[Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver]Eli Zuckerman, Rifaat Safadi, Ran Oren, et al.
Annals of Hepatology|August 11, 2015
Secondary sclerosing cholangitis following major burnZiv Ben-Ari, David Levingston, Ella Weitzman, et al.
Journal of Hepatology|June 17, 2017
Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimerasSimone Susser, Julia Dietz, Bernhard Schlevogt, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2011
Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US dataDavid Kershenobich, Homie A Razavi, Curtis L Cooper, et al.
Journal of Hepatology|April 22, 2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agentXavier Forns, Stuart C Gordon, Eli Zuckerman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2015
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGEMaria Buti, Stuart C Gordon, Eli Zuckerman, et al.
Journal of Clinical Microbiology|May 3, 2019
Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 ChimerasKai-Henrik Peiffer, Lisa Kuhnhenn, Evelyn Stelzl, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2020
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus InfectionEli Zuckerman, Julio A Gutierrez, Douglas E Dylla, et al.
Lancet (London, England)|October 13, 2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyDavid Roth, David R Nelson, Annette Bruchfeld, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|April 11, 2026
EXPRESS: Adherence and Sustained Virologic Response in HCV Treatment: A Real-World Comparison of Major Pangenotypic Direct-Acting AntiviralsFadi Abu Baker, Rawi Hazzan, Tarek Saadi, et al.
Harefuah|January 22, 2013
[Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver]Eli Zuckerman, Rifaat Safadi, Ran Oren, et al.
Annals of Hepatology|August 11, 2015
Secondary sclerosing cholangitis following major burnZiv Ben-Ari, David Levingston, Ella Weitzman, et al.
Journal of Hepatology|June 17, 2017
Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimerasSimone Susser, Julia Dietz, Bernhard Schlevogt, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2011
Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US dataDavid Kershenobich, Homie A Razavi, Curtis L Cooper, et al.
Journal of Hepatology|April 22, 2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agentXavier Forns, Stuart C Gordon, Eli Zuckerman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2015
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGEMaria Buti, Stuart C Gordon, Eli Zuckerman, et al.
Journal of Clinical Microbiology|May 3, 2019
Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 ChimerasKai-Henrik Peiffer, Lisa Kuhnhenn, Evelyn Stelzl, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2020
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus InfectionEli Zuckerman, Julio A Gutierrez, Douglas E Dylla, et al.
Lancet (London, England)|October 13, 2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyDavid Roth, David R Nelson, Annette Bruchfeld, et al.
Pageof 4